FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193455869> ?p ?o ?g. }

• W3193455869 abstract "Background: The hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DAC) have been widely used in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS). However, few direct clinical trials have been carried out to compare the efficacy and adverse events (AEs) between these two agents. The clinical choice between them is controversial. A systematic review and network meta-analysis (NMA) was performed to compare the efficacy, safety, and survival of DAC and AZA in AML and HR-MDS patients. Methods: We systematically searched MEDLINE, Embase, Web of Science, and Cochrane Library through March 15, 2021. Randomized controlled trials (RCTs) on AML or HR-MDS patients comparing the efficacy and safety between DAC and AZA or comparing one of HMAs to conventional care regimens (CCR) were selected. Results: Eight RCTs ( n = 2,184) were identified in the NMA. Four trials compared AZA to CCR, and four compared DAC to CCR. Direct comparisons indicated that, compared to CCR, both AZA and DAC were associated with higher overall response (OR) rate (AZA vs. CCR: relative risk (RR) = 1.48, 95% CI 1.05–2.1; DAC vs. CCR: RR = 2.14, 95% CI 1.21–3.79) and longer overall survival (OS) (AZA vs. CCR: HR = 0.64, 95% CI 0.50–0.82; DAC vs. CCR: HR = 0.84, 95% CI 0.72–0.98), and AZA showed higher rate of complete remission with incomplete blood count recovery (CRi) (HR = 2.52, 95% CI 1.27–5). For the indirect method, DAC showed a higher complete remission (CR) rate than AZA in patients with both AML (RR = 2.28, 95% CI 1.12–4.65) and MDS (RR = 7.57, 95% CI 1.26–45.54). Additionally, DAC significantly increased the risk of 3/4 grade anemia (RR = 1.61, 95% CI: 1.03–2.51), febrile neutropenia (RR = 4.03, 95% CI: 1.41–11.52), and leukopenia (RR = 3.43, 95% CI 1.64–7.16) compared with AZA. No statistical significance was found for the other studied outcomes. Conclusion: Compared to CCR, both AZA and DAC can promote outcomes in patients with AML and HR-MDS. DAC showed higher efficacy especially CR rate than AZA (low-certainty evidence), while AZA experienced lower frequent grade 3/4 cytopenia than patients receiving DAC treatment." @default.
• W3193455869 created "2021-08-30" @default.
• W3193455869 creator A5029197578 @default.
• W3193455869 creator A5068758349 @default.
• W3193455869 date "2021-08-17" @default.
• W3193455869 modified "2023-10-11" @default.
• W3193455869 title "Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis" @default.
• W3193455869 cites W1600365609 @default.
• W3193455869 cites W1840418402 @default.
• W3193455869 cites W2001307836 @default.
• W3193455869 cites W2010699829 @default.
• W3193455869 cites W2017394727 @default.
• W3193455869 cites W2040311067 @default.
• W3193455869 cites W2040557955 @default.
• W3193455869 cites W2057798569 @default.
• W3193455869 cites W2081279521 @default.
• W3193455869 cites W2081576971 @default.
• W3193455869 cites W2083583944 @default.
• W3193455869 cites W2085803274 @default.
• W3193455869 cites W2100190476 @default.
• W3193455869 cites W2106082819 @default.
• W3193455869 cites W2106084333 @default.
• W3193455869 cites W2106584820 @default.
• W3193455869 cites W2106833395 @default.
• W3193455869 cites W2118771330 @default.
• W3193455869 cites W2121710010 @default.
• W3193455869 cites W2126930838 @default.
• W3193455869 cites W2140559350 @default.
• W3193455869 cites W2148660548 @default.
• W3193455869 cites W2157287007 @default.
• W3193455869 cites W2159507916 @default.
• W3193455869 cites W2330246487 @default.
• W3193455869 cites W2467917196 @default.
• W3193455869 cites W2769593777 @default.
• W3193455869 cites W2771627443 @default.
• W3193455869 cites W2888303152 @default.
• W3193455869 cites W2888771996 @default.
• W3193455869 cites W2891824084 @default.
• W3193455869 cites W2910473124 @default.
• W3193455869 cites W2942855506 @default.
• W3193455869 cites W2993198099 @default.
• W3193455869 cites W3010574923 @default.
• W3193455869 cites W3012563958 @default.
• W3193455869 cites W3133237233 @default.
• W3193455869 cites W3143399220 @default.
• W3193455869 doi "https://doi.org/10.3389/fphar.2021.701690" @default.
• W3193455869 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8416074" @default.
• W3193455869 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34483903" @default.
• W3193455869 hasPublicationYear "2021" @default.
• W3193455869 type Work @default.
• W3193455869 sameAs 3193455869 @default.
• W3193455869 citedByCount "20" @default.
• W3193455869 countsByYear W31934558692022 @default.
• W3193455869 countsByYear W31934558692023 @default.
• W3193455869 crossrefType "journal-article" @default.
• W3193455869 hasAuthorship W3193455869A5029197578 @default.
• W3193455869 hasAuthorship W3193455869A5068758349 @default.
• W3193455869 hasBestOaLocation W31934558691 @default.
• W3193455869 hasConcept C104317684 @default.
• W3193455869 hasConcept C126322002 @default.
• W3193455869 hasConcept C143998085 @default.
• W3193455869 hasConcept C150194340 @default.
• W3193455869 hasConcept C168563851 @default.
• W3193455869 hasConcept C185592680 @default.
• W3193455869 hasConcept C190727270 @default.
• W3193455869 hasConcept C197934379 @default.
• W3193455869 hasConcept C2776239401 @default.
• W3193455869 hasConcept C2776478404 @default.
• W3193455869 hasConcept C2778729363 @default.
• W3193455869 hasConcept C2780007613 @default.
• W3193455869 hasConcept C2780235182 @default.
• W3193455869 hasConcept C2780240888 @default.
• W3193455869 hasConcept C2780817109 @default.
• W3193455869 hasConcept C44249647 @default.
• W3193455869 hasConcept C535046627 @default.
• W3193455869 hasConcept C55493867 @default.
• W3193455869 hasConcept C71924100 @default.
• W3193455869 hasConcept C82789193 @default.
• W3193455869 hasConcept C95190672 @default.
• W3193455869 hasConceptScore W3193455869C104317684 @default.
• W3193455869 hasConceptScore W3193455869C126322002 @default.
• W3193455869 hasConceptScore W3193455869C143998085 @default.
• W3193455869 hasConceptScore W3193455869C150194340 @default.
• W3193455869 hasConceptScore W3193455869C168563851 @default.
• W3193455869 hasConceptScore W3193455869C185592680 @default.
• W3193455869 hasConceptScore W3193455869C190727270 @default.
• W3193455869 hasConceptScore W3193455869C197934379 @default.
• W3193455869 hasConceptScore W3193455869C2776239401 @default.
• W3193455869 hasConceptScore W3193455869C2776478404 @default.
• W3193455869 hasConceptScore W3193455869C2778729363 @default.
• W3193455869 hasConceptScore W3193455869C2780007613 @default.
• W3193455869 hasConceptScore W3193455869C2780235182 @default.
• W3193455869 hasConceptScore W3193455869C2780240888 @default.
• W3193455869 hasConceptScore W3193455869C2780817109 @default.
• W3193455869 hasConceptScore W3193455869C44249647 @default.
• W3193455869 hasConceptScore W3193455869C535046627 @default.
• W3193455869 hasConceptScore W3193455869C55493867 @default.
• W3193455869 hasConceptScore W3193455869C71924100 @default.
• W3193455869 hasConceptScore W3193455869C82789193 @default.
• W3193455869 hasConceptScore W3193455869C95190672 @default.

• next